


September 28, 2018



MyDx Analyzer to be Used in Large HIV Study by the University of Florida

SAN DIEGO, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - [MyDx, Inc.](#) (OTC: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the [CannaDx Analyzer](#), in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.



“With this study, we are taking an additional step in solidifying our position as a leader in science based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx. “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.”

We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.

This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.

Marijuana and Potential Long-term Effects Study Goals

The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation.

The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years.

During a visit, participants will be asked to:

- Give a small blood sample
- Give a small urine sample
- Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood
- Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad

The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects).

The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself, and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.

The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit.

About MyDx, Inc.

MyDx, Inc. ([OTC: MYDX](#)) is a leader in science based cannabis health technology with a focus on implementing a strategy designed to have it become a highly desired acquisition target for big pharma or another entity interested in the powerful data MyDx is accumulating in the emerging global cannabis market. MyDx is working on implementing this vision by creating some of the most advanced consumer smart devices, applications and services all working together towards creating one of the largest and intelligent crowdsourced consumer as well as medical study and patient feedback databases that ties physiological effects to specific cannabinoid and terpene profiles. This is the kind of database that can drive the future of medicine for the global cannabis industry.

Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities

Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at <http://ir.cdxlife.com/all-sec-filings> or www.sec.gov.

Attachment

- [MyDX](#)

Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@mydxlife.com



Source: MyDx, Inc.